GlassScriptPhysician profile
Melissa Jane Boyle
NPI 1770718678
$4,730.55
in general payments reported to CMS, 2019-2025
25 companies · $761 in 2025
The $761 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,239 · 2022: $577 · 2023: $1,156 · 2024: $997 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,914.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,441.27 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $616.90 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $400.71 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $399.40 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $335.50 | 2021-2024 | Caplyta |
| Alkermes, INC. | $299.15 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $258.37 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $239.66 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $219.92 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $108.43 | 2021-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $65.22 | 2021 | |
| Bausch Health US, LLC | $56.20 | 2023-2024 | Wellbutrin, Aplenzin |
| Indivior INC. | $36.20 | 2024-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $28.75 | 2023-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $28.20 | 2024-2025 | Adzenys Xr-Odt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $25.00 | 2023 | Inspire |
| Orexo US, INC. | $21.35 | 2023 | Zubsolv |
| Tris Pharma INC | $21.32 | 2025 | Dyanavel Xr |
| Almatica Pharma LLC | $21.24 | 2023 | Gralise |
| Neurocrine Biosciences, INC. | $19.34 | 2025 | |
| Corium, LLC | $19.17 | 2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $18.43 | 2022 | |
| Braeburn INC. | $18.04 | 2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $16.99 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $15.79 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.